[{"id":"c40fa03c-9c20-4928-9562-c4d2f144ca96","acronym":"DAR-UM-2","url":"https://clinicaltrials.gov/study/NCT05987332","created_at":"2023-08-14T15:10:06.767Z","updated_at":"2025-02-25T16:27:34.251Z","phase":"Phase 2/3","brief_title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","source_id_and_acronym":"NCT05987332 - DAR-UM-2","lead_sponsor":"IDEAYA Biosciences","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Xalkori (crizotinib) • Yervoy (ipilimumab) • dacarbazine • darovasertib (IDE196)"],"overall_status":"Recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 01/15/2028","study_completion_date":" 01/15/2028","last_update_posted":"2025-02-04"}]